Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Articles

12351 items
9:01 PM, Oct 09, 2018  |  BC Extra | Financial News

Versant-backed Gotham raises $54M series A

Versant Ventures unveiled a move into the RNA metabolism space with an investment in Gotham Therapeutics (New York, N.Y.). Versant co-led a $54 million series A round with Forbion Capital Partners and SR One. Gotham is...
1:10 PM, Oct 09, 2018  |  BC Extra | Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
2:37 PM, Oct 08, 2018  |  BC Extra | Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Monday with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough runway...
1:40 PM, Oct 08, 2018  |  BC Extra | Financial News

5AM looking for $350M sixth fund

5AM Ventures aims to raise $350 million for its sixth fund, according to an SEC filing. The firm raised $285 million for its fifth fund, which closed in May 2016. 5AM led or co-led recent investments...
11:22 AM, Oct 05, 2018  |  BC Extra | Financial News

JHL raises financing at $750M valuation

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised an undisclosed amount in a private financing at a valuation of $750 million. Participating in the financing were Sanofi (Euronext:SAN; NYSE:SNY) and other undisclosed investors, according to...
6:08 AM, Oct 05, 2018  |  BC Extra | Financial News

Gene therapy developer Orchard proposes IPO

Orchard Therapeutics Ltd. (London, U.K.) proposed to raise up to $172.5 million in an IPO on NASDAQ. J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow are underwriters. Orchard is developing autologous ex vivo lentiviral gene therapies...
7:06 AM, Oct 04, 2018  |  BC Extra | Financial News

Guardant gets pop after IPO; Kodiak prices below range

Liquid biopsy company Guardant Health Inc. (NASDAQ:GH) and ophthalmic company Kodiak Sciences Inc. (NASDAQ:KOD) each priced IPOs late Wednesday. Guardant priced above its proposed range and posted a big gain on Thursday, while Kodiak priced...
12:09 PM, Oct 03, 2018  |  BC Extra | Financial News

GW, Epizyme, Kala price follow-ons

GW Pharmaceuticals plc (NASDAQ:GWPH), Epizyme Inc. (NASDAQ:EPZM) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) each priced follow-ons late Tuesday, raising a total of $437 million. GW raised $300 million through the sale of 1.9 million ADSs at $158...
3:58 PM, Oct 02, 2018  |  BC Extra | Financial News

Allogene IPO could be year's largest biotech listing on NASDAQ

In newly proposed terms for its planned IPO on NASDAQ, cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) hopes to sell 16 million shares at $16-$18. At the midpoint, Allogene would raise $272...
2:45 PM, Oct 01, 2018  |  BC Extra | Financial News

Modis raises $30M series A for mitochondrial disorders

F-Prime Capital Partners and OrbiMed Advisors led a $30 million series A round for rare genetic disease company Modis Therapeutics Inc. (Oakland, Calif.). The round also included founding investor Aceras Life Sciences and new investor...

Pages